Genmab A/S (GMAB) Stock Forecast & Price Target

$24.33

+0.21 (+0.87%)

(As of 09/27/2024 ET)

Genmab A/S - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 13 Analyst Ratings

Sell
2

Hold
3

Buy
8

Based on 13 Wall Street analysts who have issued ratings for Genmab A/S in the last 12 months, the stock has a consensus rating of "Hold." Out of the 13 analysts, 2 have given a sell rating, 3 have given a hold rating, and 8 have given a buy rating for GMAB.

Consensus Price Target

$45.20
85.78% Upside

According to the 13 analysts' twelve-month price targets for Genmab A/S, the average price target is $45.20. The highest price target for GMAB is $50.00, while the lowest price target for GMAB is $31.00. The average price target represents a forecasted upside of 85.78% from the current price of $24.33.

Get the Latest News and Ratings for GMAB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Genmab A/S and its competitors.

GMAB Analyst Ratings Over Time

Type	Current Forecast 9/30/23 to 9/29/24	1 Month Ago 8/31/23 to 8/30/24	3 Months Ago 7/2/23 to 7/1/24	1 Year Ago 9/30/22 to 9/30/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)
Hold	3 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	7 Hold rating(s)
Sell	2 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$45.20	$49.50	$49.50	$46.00
Forecasted Upside	85.78% Upside	78.06% Upside	99.20% Upside	30.42% Upside
Consensus Rating	Hold	Hold	Hold	Hold

“Buffett Indicator” Predicts 62% Stock Market Crash (Ad)

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>

GMAB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GMAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Genmab A/S Stock vs. The Competition

Type	Genmab A/S	Medical Companies	S&P 500
Consensus Rating Score	2.46	2.78	2.50
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	85.78% Upside	818.50% Upside	6.16% Upside
News Sentiment Rating	Neutral News See Recent GMAB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/20/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00	+88.82%
9/11/2024	Morgan Stanley 3 of 5 stars		Reiterated Rating	Equal Weight ➝ Equal Weight	$31.00 ➝ $31.00	+15.63%
9/9/2024	Truist Financial 2 of 5 stars		Lower Target	Buy ➝ Buy	$53.00 ➝ $50.00	+82.55%
8/20/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Neutral
7/15/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Campbell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Outperform
6/27/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$46.00 ➝ $47.00	+83.09%
Get the Latest News and Ratings for GMAB and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.
2/23/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$46.00 ➝ $48.00	+64.89%
1/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Sell
12/6/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy
11/10/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
11/8/2023	DNB Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Buy
10/18/2023	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Underperform
10/12/2023	Nordea Equity Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
2/23/2023	Danske Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
2/6/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform	$33.00 ➝ $36.00	-5.91%
11/17/2022	AlphaValue Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Reduce
11/15/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$43.00	-0.23%
11/14/2022	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:22 PM ET.

Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 24, 2024. Please send any questions or comments about these Genmab A/S pros and cons to contact@marketbeat.com.

Genmab A/S
Bull Case

Here are some ways that investors could benefit from investing in Genmab A/S:

Genmab A/S has a strong market capitalization of $18.16 billion, indicating stability and potential for growth.
The company's return on equity of 17.48% showcases its ability to generate profit from shareholders' equity.
Analysts predict Genmab A/S will post 1.21 EPS for the current year, indicating positive earnings potential.
Genmab A/S stock has a relatively low P/E ratio of 22.88, suggesting it may be undervalued compared to its earnings.
Recent analyst ratings have been positive, with a consensus price target of $45.20, indicating potential for stock price appreciation.

Genmab A/S
Bear Case

Investors should be bearish about investing in Genmab A/S for these reasons:

Genmab A/S stock has experienced a decline in target price from $53.00 to $50.00, potentially signaling concerns among analysts.
Two research analysts have rated the stock as sell, indicating some skepticism about its performance.
The stock's 12-month high of $38.80 suggests potential volatility in its price movements.
Genmab A/S missed analysts' consensus estimates for earnings per share in the last quarter, which may raise concerns about its financial performance.
The stock's beta of 0.99 indicates it moves in line with the market, potentially limiting opportunities for outperformance.

GMAB Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Genmab A/S is $45.20, with a high forecast of $50.00 and a low forecast of $31.00.
: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There are currently 2 sell ratings, 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares.
: According to analysts, Genmab A/S's stock has a predicted upside of 85.78% based on their 12-month stock forecasts.
: Over the previous 90 days, Genmab A/S's stock had 1 upgrade by analysts.
: Genmab A/S has been rated by research analysts at HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Royal Bank of Canada, and Truist Financial in the past 90 days.
: Analysts like Genmab A/S less than other "medical" companies. The consensus rating for Genmab A/S is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GMAB compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Kamala’s tax plan is worse than you think—find out why (Ad)

Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.

Get your FREE, no-obligation Wealth Protection Guide now

This page (NASDAQ:GMAB) was last updated on 9/29/2024 by MarketBeat.com Staff

From Our Partners